Divya Gupta, MD, assistant professor at Feinberg School of Medicine at Northwestern University, discussed the potential of using circulating tumor DNA and minimal residual disease (MRD) assays for ...
Cancer continues to be one of the most challenging diseases to treat worldwide. The three main methods used to treat cancer are surgical excision, chemotherapy, and radiation therapy. Immunotherapy ...
High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably Identified in Colorectal Cancer (CRC MSI-H) and Non-Small Cell ...
The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.
Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...
Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...
Already the go-to drug of choice for millions with type 2 diabetes, metformin might also fight lung cancer if those patients ...
The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.
The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its ...
Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...
The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...
CNSide can aid the diagnosis and management of leptomeningeal metastases in patients with cancer, a new study suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback